Analysis Of The Efficacy And Compliance Of Sublingual Immunotherapy With Single And Monosensitized Allergic Rhinitis

Objective:To explore the efficacy and compliance of sublingual immunotherapy(SLIT)with single and monosensitized allergic rhinitis(AR)patients.Methods:120 patients with AR were treated with sublingual immunotherapy in the second hospital of Shanxi Medical University from January 2017,There are 56 cases in mitesingle group,25 cases completed 2-year SLIT,and 64 cases in monosensitized group,29 cases completed 2-year,the symptom drug score(CSMS)before and after treatment was compared between the two groups,adverse reactions were recorded,efficacy,influencing factors were analyzed.Methods: a total of 120 patients who received sublingual immunotherapy(SLIT)since January 2017 and were followed up successfully were retrospectively analyzed.There were 56 patients with AR caused by only one allergen.Among them,25 patients successfully completed SLIT treatment for 24 months;There were 64 patients with ARnot caused by a kind of sensitizing substance,among which 29 patients successfully completed the 24 month SLIT treatment.The symptom drug combination score(CSMs)of the two groups before and after treatment was compared,the adverse reactions were recorded,and the efficacy,influencing factors were analyzed Results:After 2 years of treatment,CSMS in both groups decreased(P< 0.05).There was no significant difference between the two groups(P> 0.05)in baseline and post-treatment CSMS group,6 patients had slight adverse reactions,SLIT compliance was not ideal.Conclusion:SLIT is effective with single and monosensitized AR,with no difference in efficacy.Low compliance is mainly affected by SLIT treatment course and efficacy.